All News

Walgreens is partnering with VillageMD to create primary care clinics in Texas

HZ in children is uncommon and is 10 times less common in kids who’ve been vaccinated against chickenpox.

Courses can be implemented alongside existing educational programs.

 The average price of generics is about one-eighteenth the price of the brand product.

Government and PBMs can pursue penalties for noncompliance. 

Reimbursement reform tops list of priorities, from DIR fees to rebates.

Key updates from the Seattle, WA, conference in March.

Evenity (romosozumab-aqqg) has been approved to treat postmenopausal women at high risk of bone fractures.

Women no longer require nine months of contraception post cessation of the drug.

First-ever dual-drug, single tablet for HIV offers lighter treatment regimen. 

Advocates are calling for government regulations on PBMs and pharmacy.  

Consumers are using test strips that might lead to inaccurate results. 

Rural markets pave way to treat underserved populations, provide value-based care, and expand prescription volume. 

The chain will use Shipt to deliver prescriptions from 6,000 locations. 

New report highlights the dangers of prescription medications beyond opioids. 

"Test and treat" scheme reducing stress on general practitioners. 

The program increased hypertension management rates to 77% in 2017. 

Tom Kraus to bring expeirence in government and industry.

Two Arizona pharmacists made headlines when it seems they may have not adhered to the Oath of the Pharmacist.

Success depends on marketing, relationship building. 

Solriamfetol is approved for adult patients suffering from the effects of narcolepsy and OSA. 

The CBD market is anticipated to be worth $20 billion by 2024.

New guide details actions for pharmacists and payers.

The next-generation oral drug is the first to be approved specifically for secondary progressive multiple sclerosis in more than 15 years.

 More than 25,000 lawsuits cite uncontrollable and irreversible bleeding and death. 

Patients taking PPIs 28.4 times more likely to develop chronic kidney disease.